Fermenta Receives Letter Of Approval From GAIN, Reinforcing Its Global Commitment To Quality And Nutrition
PRNewswire
Mumbai (Maharashtra) [India], May 17: Fermenta Biotech Limited, a leading player in the field of nutritional ingredients and food fortification, is pleased to announce that it has received the Letter Of Approval (LOA) by the Global Alliance for Improved Nutrition (GAIN) as a supplier of dry and liquid premix blends. This prestigious certification recognises Fermenta's steadfast commitment to global benchmarks of quality, food safety, and nutritional excellence.
The LOA reinforces Fermenta's position as a reliable and trusted supplier of high-quality, nutritionally enriched products, in line with its mission to support improved health outcomes and nutritional security across the globe. The achievement further empowers Fermenta to contribute notably to global public health and food fortification efforts.
Established in 2009, the GAIN Premix Facility (GPF) aims to combat malnutrition by supporting the food industry in the fortification of essential staples such as wheat flour, oil, salt, rice, and maize. The GPF ensures rigorous quality control by building a trusted network of prequalified premix blenders and micronutrient suppliers, thereby alleviating the need for independent audits by food producers. Additionally, the GPF facilitates competitive and transparent tendering processes to make high-quality premixes and micronutrients accessible and cost-effective.
Commenting on the achievement, Prashant Nagre, Managing Director of Fermenta, shared:
"The GAIN certification stands as a testament to the relentless dedication and expertise of our team in upholding the highest standards of safety, quality, and nutritional integrity. We are honoured to contribute to the global movement for food security and fortification, and remain firmly committed to improving health outcomes and well-being for communities around the world."
As an approved GPF supplier, Fermenta aims to strengthen its global presence and underscores its continued dedication to delivering safe, effective, and innovative nutritional solutions.
About Fermenta Biotech Limited:
Founded in 1951, Fermenta Biotech Limited (Fermenta) possesses a growing portfolio of nutrition, including Customized Premixes, Fortified Rice Kernel (FRK) and other nutritional ingredients. Apart from its nutrition portfolio, Fermenta is the only manufacturer of Vitamin D3 in India and a leading global player. It caters to 350+ customers across 60+ countries with a worldwide distribution network for a variety of applications such as pharmaceuticals, dietary and nutritional supplements, food, and animal nutrition. Fermenta's manufacturing facilities in Kullu, Dahej and Tirupati are certified by global accreditations, and its world-class R & D centre is located at Thane. Fermenta also possesses expertise in green chemistry such as enzymes for antibiotic synthesis, other niche APIs and environmental solutions.
For more information about Fermenta and its businesses, please visit our website: www.fermentabiotech.com.
Safe Harbor:
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Fermenta assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
21 hours ago
- Mint
Reliance Power share price jumps 8% to fresh 52-week high; Should you buy?
Reliance Power share price extended its upward momentum for the third consecutive session on Monday, surging nearly 8% to hit a fresh 52-week high amid robust trading volumes. The Anil Ambani-led Reliance Power shares rallied as much as 7.79% to touch a new high of ₹ 62.80 apiece on the BSE. This latest gain in Reliance Power shares follows an impressive 11% jump in the previous session, bringing the stock's one-week gain to over 21%. Trading volumes in Reliance Power shares were significantly elevated, with around 61 crore shares changing hands on Monday — more than double its one-week average of 27 crore shares, and nearly five times the one-month average of 13 crore shares. The surge in trading activity and stock price follows the announcement of a major renewable energy project win. Reliance Power on May 28 announced that its subsidiary, Reliance NU Energies Private Limited (Reliance NU Energies), received the Letter of Award (LOA) from SJVN, a Navratna Central Public Sector Enterprise, for a 350 MW inter-state transmission system (ISTS)-connected solar power project coupled with a 175 MW/700 MWh Battery Energy Storage System (BESS). Once commissioned, the platform will add 600 MW of solar DC capacity, and 700 MWh of BESS capacity to Reliance Power's portfolio. The company's total clean energy pipeline now stands at 2.4 GW of Solar DC capacity and over 2.5 GWH of BESS capacity, making it India's largest player in the integrated Solar + BESS segment, Reliance Power said in a regulatory filing on May 28, 2025. Reliance NU Energies had earlier emerged as the successful bidder in the competitive auction conducted by SJVN, securing the project at a fixed tariff of ₹ 3.33 per kWh for a period of 25 years. Reliance Power share price has delivered stellar returns in recent months. The Anil Ambani Group stock is up 53% over the past one month and 85% over the last three months. On a year-to-date (YTD) basis, Reliance Power shares have gained 38%, while delivering multibagger returns of 151% over the past one year. The rally has been even more pronounced over the long term, with the Reliance Power stock price rising 370% in two years and an astounding 2,800% over the last five years. From a technical perspective, Reliance Power is currently the strongest performer among Anil Dhirubhai Ambani Group (ADAG) stocks. The stock recently broke out of a 33-week-long 'cup and handle' formation on the weekly chart, noted Anshul Jain, Head of Research at Lakshmishree Investments. 'The breakout was backed by volumes 8x higher than the 50-day average, indicating strong, broad-based participation. Reliance Power share price is currently holding above the breakout level, and any dip towards ₹ 48 or consolidation around this zone presents a fresh buying opportunity,' Jain said. The pattern projects an immediate upside target of ₹ 65, with a further potential move towards ₹ 79, he added. At 12:40 PM, Reliance Power share price was trading 6.52% higher at ₹ 61.95 apiece on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
5 days ago
- Business Standard
Fermenta FY25 Revenues INR 481.3 cr, up 39% YoY; Net Profit INR 76.4 cr vs year-ago loss
PRNewswire Mumbai (Maharashtra) [India], May 29: Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, today announced that its consolidated revenue (other than from real estate) for the financial year ended 31 March 2025 was INR 427.0 crore, up 57% from the same year-ago period; EBITDA for FY25 was INR 83.3 crore against loss of INR 22.3 crore a year Revenue for FY25 INR 481.3 crore, up by INR 134 crore YoY. Consolidated EBITDA for FY25 INR 121.6 crore, up 209% YoY. Q4FY25 Consolidated Revenues INR 143.7 crore, up 40% YoY; down 9% QoQ. Performance highlights * Human nutrition volume grew by 48% over FY24 * Animal nutrition volume grew by 24% over FY24 * The company successfully completed validation batches for its spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition - Vitamin D3 100 SD and started qualification process with leading global customers and regulatory authorities. * The company also successfully completed commercial scale production of its plant based Vitamin D3 active ingredient using its proprietary technology developed in-house and completed validation batches of its plant based D3 in Oil and D3 spray dried powder variants for human nutrition-Vitadee Green™ 1 MIU Oil and Vitadee Green™ 100 SD and started qualification process with leading global customers and regulatory authorities. * Fermenta received letter of approval from GAIN, reinforcing its global commitment to quality and nutrition * Our German subsidiary showed standalone FY25 revenue of INR 38.2 crore, 412% growth from INR 7.5 crore a year ago, with EBITDA of INR 13.9 crore, against loss of INR 9.2 crore a year ago. Our US subsidiary showed revenue of INR 50.4 crore, up 81% from INR 27.8 crore a year ago with EBITDA at INR 0.5 crore loss, against INR 1.6 crore loss a year ago Commenting on the results, Prashant Nagre, Managing Director, said: "FY25 marks Fermenta's complete operational turnaround, validating our strategic focus and unwavering commitment to excellence. Strong volume recovery in our core Vitamin D3 business, successful geographic expansion across Latin America and Southeast Asia, and breakthrough innovations like Vitadee Green™--the world's first pharmacopeial-grade plant-based Vitamin D3--demonstrate our resilience and technical leadership. With strong cash flows, improved margins across all product lines, and new value-added products gaining meaningful market traction, we've built a robust foundation for sustained growth. Our disciplined approach to capital allocation, proactive risk management, and strategic partnerships position us to capitalize on emerging opportunities while advancing our vision of top-quality global nutritional wellness for all." About Fermenta Biotech Limited Fermenta Biotech Limited delivers best in class, science-backed nutritional ingredients across a wide range of market segments, including Pharmaceuticals, Dietary Supplements, Food & Beverages, and Veterinary. State-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh) and Dahej (Gujarat) drive FBL's comprehensive portfolio of premium vitamins, nutritional premixes, and ingredients for Human and Animal Nutrition. Our products and services cater to the exacting standards of the world's leading pharma, dietary supplements and food brands, and veterinary and animal feed producers for best-in-class solutions that enhance health, support preventive care, and drive life productivity. With decades of expertise at global-scale complex manufacturing, we also provide research-based custom solutions in green chemistry and environmental solutions. Financial Statements can be accessed through this link: Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this release. Such information and opinions are in all events not current after the date of this release. Certain statements made in this release may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Fermenta Biotech Limited ("Company" or "FBL" or Fermenta), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this release are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This release is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This release does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. This release is confidential and may not be copied or disseminated, in whole or in part, and in any manner. For further details, please contact: For Fermenta Biotech Limited:
Time of India
21-05-2025
- Time of India
IRCON International shares in focus after Rs 254 crore KAVACH contract from South Western Railway
Shares of state-run IRCON International will be in focus on Wednesday after the company announced it has secured a Rs 253.6 crore contract from South Western Railway for the implementation of KAVACH , an indigenous train collision avoidance system . The system will be deployed across 778 route kilometers in the Bengaluru and Mysuru divisions. The contract includes the survey, design, supply, installation, testing, and commissioning of KAVACH equipment along with associated works. The project is expected to be completed within 18 months from the date of issuance of the Letter of Acceptance (LOA). Also Read: KEC International, PVR INOX among 10 smallcap stocks analysts expect to gain up to 80% IRCON International reported a 3.8% year-on-year (YoY) decline in net profit to Rs 246.8 crore for the fourth quarter ended 31st March, 2024, compared to Rs 256.5 crore in the same period last year. The company's revenue from operations fell 1% to Rs 3,742.7 crore versus Rs 3,780.7 crore in the corresponding period of the preceding fiscal. At the operating level, EBITDA dipped 56.3% to Rs 286.3 crore in the fourth quarter of this fiscal over Rs 183.2 crore in the year-ago period. Live Events The EBITDA margin stood at 7.7% in the reporting quarter compared to 4.9% in the fourth quarter of the previous fiscal. Also Read: Street Favourite! SBI, Tata Motors among 10 large-cap stocks analysts expect to rally up to 32% IRCON International share price target According to Trendlyne, the average target price for IRCON International is Rs 147, indicating a downside of 22% from current levels. The stock holds a 'Sell' rating based on recommendations from 3 analysts. IRCON International shares price performance IRCON shares have risen 17% in the past three months but are down 31% over the past 12 months. The company's market capitalisation currently stands at Rs 17,709 crore. Also Read: Crompton Greaves, Delhivery among 10 mid-cap stocks analysts expect to rally up to 53% ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
